Scholarlink

Background <p>Limited data is available for long-term outcomes after percutaneous coronary intervention (PCI) of coronary drug-eluting stent (DES) in-stent restenosis (ISR) in diabetics.</p> Aims <p>Thus, the aim of this observational, retrospective study was to close this lack of evidence.</p> Methods <p>Between January 2007 and February 2021, a total of 3511 patients with 5497 ISR lesions were treated at two large-volume centers in Munich, Germany, of which 1242 (35.4%) were diabetics. Endpoints of interest were the rates of cardiac death, repeat revascularization, and myocardial infarction (MI). Survival was analyzed using the Kaplan–Meier method. Differences between the groups were tested with the log-rank test. Conventional multivariable analysis with adjustment for relevant variables was performed.</p> Results <p>After 10 years, the rates of cardiac death were 42.8% for diabetics and 32.8% for nondiabetics (HR<sub>adj</sub> 1.55 [95% CI, 1.31–1.81], <i>p</i> &lt; 0.001). MI occurred in 15.9% of diabetics and in 9.7% of non-diabetics (HR<sub>adj</sub> 1.70 [95% CI, 1.36–2.11], <i>p</i> &lt; 0.001). The rates of repeat revascularization of target lesion (HR<sub>adj</sub> 1.17 [95% CI, 1.02–1.34], <i>p</i> = 0.028), target vessel, and nontarget vessel were significantly higher in diabetics as compared to nondiabetics. No statistically relevant difference was found regarding the rate of stent thrombosis. Compared to non-insulin-dependent diabetics, insulin-dependent diabetics show higher rates of cardiac death and MI, but comparable revascularization rates in both diabetic groups.</p> Conclusions <p>In the long term, the rates of cardiac death, MI, and repeat revascularization after PCI of DES-ISR are significantly higher in diabetics, particularly in insulin-dependent diabetics, than in nondiabetics.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diabetes-related ten-year outcomes after percutaneous coronary intervention of in-stent restenosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Constantin Kuna,
  • Eduard Braun,
  • Christian Bradaric,
  • Tobias Koch,
  • Antonia Presch,
  • Felix Voll,
  • Sebastian Kufner,
  • Tareq Ibrahim,
  • Heribert Schunkert,
  • Karl-Ludwig Laugwitz,
  • Salvatore Cassese,
  • Adnan Kastrati,
  • Jens Wiebe

摘要

Background

Limited data is available for long-term outcomes after percutaneous coronary intervention (PCI) of coronary drug-eluting stent (DES) in-stent restenosis (ISR) in diabetics.

Aims

Thus, the aim of this observational, retrospective study was to close this lack of evidence.

Methods

Between January 2007 and February 2021, a total of 3511 patients with 5497 ISR lesions were treated at two large-volume centers in Munich, Germany, of which 1242 (35.4%) were diabetics. Endpoints of interest were the rates of cardiac death, repeat revascularization, and myocardial infarction (MI). Survival was analyzed using the Kaplan–Meier method. Differences between the groups were tested with the log-rank test. Conventional multivariable analysis with adjustment for relevant variables was performed.

Results

After 10 years, the rates of cardiac death were 42.8% for diabetics and 32.8% for nondiabetics (HRadj 1.55 [95% CI, 1.31–1.81], p < 0.001). MI occurred in 15.9% of diabetics and in 9.7% of non-diabetics (HRadj 1.70 [95% CI, 1.36–2.11], p < 0.001). The rates of repeat revascularization of target lesion (HRadj 1.17 [95% CI, 1.02–1.34], p = 0.028), target vessel, and nontarget vessel were significantly higher in diabetics as compared to nondiabetics. No statistically relevant difference was found regarding the rate of stent thrombosis. Compared to non-insulin-dependent diabetics, insulin-dependent diabetics show higher rates of cardiac death and MI, but comparable revascularization rates in both diabetic groups.

Conclusions

In the long term, the rates of cardiac death, MI, and repeat revascularization after PCI of DES-ISR are significantly higher in diabetics, particularly in insulin-dependent diabetics, than in nondiabetics.

Graphical Abstract